High dose statin treatment can help restore sight
London: A common cholesterol-lowering drug statin can restore vision in the patients with a hard-to-treat version of the leading cause of blindness in the developed world, according to a new research.
Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins for the treatment of patients with the dry form of age-related macular degeneration (AMD).
The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.
Their findings not only further the connection between lipids, AMD and atherosclerosis, but also present a potential therapy for some patients with dry AMD.
Researcher Joan W. Miller said that they found that intensive doses of statins carry the potential for clearing up the lipid debris that can lead to vision impairment in a subset of patients with macular degeneration.
Miller added that the researchers hope that this promising preliminary clinical trial will be the foundation for an effective treatment for millions of patients afflicted with AMD.
Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins for the treatment of patients with the dry form of age-related macular degeneration (AMD).
The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.
Their findings not only further the connection between lipids, AMD and atherosclerosis, but also present a potential therapy for some patients with dry AMD.
Researcher Joan W. Miller said that they found that intensive doses of statins carry the potential for clearing up the lipid debris that can lead to vision impairment in a subset of patients with macular degeneration.
Miller added that the researchers hope that this promising preliminary clinical trial will be the foundation for an effective treatment for millions of patients afflicted with AMD.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.